ストックスクリーナーアプリを入手
1.41
0.70%
-0.01
アフターアワーズ：
1.35
-0.06
-4.26%
前日終値:
$1.42
開ける：
$1.42
24時間の取引高:
300.82K
Relative Volume:
0.83
時価総額：
$115.06M
収益：
-
当期純損益:
$-21.65M
株価収益率:
-4.2457
EPS:
-0.3321
ネットキャッシュフロー:
$-15.84M
1週間 パフォーマンス:
-3.42%
1か月 パフォーマンス:
+10.16%
6か月 パフォーマンス:
-34.72%
1年 パフォーマンス:
+15.57%
1日の値動き範囲:
$1.36
$1.46
1週間の範囲:
$1.26
$1.475
52週間の値動き範囲:
$0.9595
$3.12
Cardiol Therapeutics Inc Stock (CRDL) Company Profile
CRDL を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRDL
Cardiol Therapeutics Inc
|
1.41 | 115.06M | 0 | -21.65M | -15.84M | -0.3321 |
|
ZTS
Zoetis Inc
|
170.90 | 77.10B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.47 | 42.82B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.39 | 42.45B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.73 | 20.09B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
151.82 | 15.37B | 2.24B | 385.90M | 440.10M | 3.73 |
Cardiol Therapeutics Inc Stock (CRDL) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-28 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-26 | 開始されました | ROTH MKM | Buy |
| 2024-04-22 | 開始されました | H.C. Wainwright | Buy |
Cardiol Therapeutics Inc (CRDL) 最新ニュース
RODMAN&RENSHAW Upgrades Cardiol Therapeutics (NASDAQ:CRDL) to "Strong-Buy" - MarketBeat
Analysts Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) PT at $8.40 - MarketBeat
Reviewing Cardiol Therapeutics (NASDAQ:CRDL) and CG Oncology (NASDAQ:CGON) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Coverage Initiated by Analysts at Rodman & Renshaw - MarketBeat
Brokerages Set Cardiol Therapeutics Inc. (NASDAQ:CRDL) Price Target at $8.40 - Defense World
Rodman & Renshaw Begins Coverage on Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Raised to Strong-Buy at RODMAN&RENSHAW - Defense World
Rodman & Renshaw sets $7 target on Cardiol Therapeutics stock - MSN
Cardiol Therapeutics (TSE:CRDL) Trading Down 3.4%What's Next? - MarketBeat
Jane Street Group LLC Takes $29,000 Position in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (TSE:CRDL) Shares Down 3.4% – Here’s What Happened - Defense World
Pericarditis Drugs Market reached US$ 544.4 million in 2023 - openPR
Critical Comparison: Black Diamond Therapeutics (NASDAQ:BDTX) & Cardiol Therapeutics (NASDAQ:CRDL) - Defense World
Top 4 Canadian Biotech Stocks (Updated January 2025) - Investing News Network
Cardiol Therapeutics Inc. (NASDAQ:CRDL) Short Interest Up 12.4% in December - MarketBeat
Appendix 3Y x4 - Investing News Network
Cardiol Therapeutics Sees Insider Buying From Leadership Team And Board Members - The Deep Dive
Guillermo Torre Purchases 17,240 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Insider Buying: Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Buys 18,900 Shares of Stock - MarketBeat
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases - Proactive Investors Australia
2025 biotech outlook: Small-cap innovators tackling chronic and rare diseases | NASDAQ:CADL - Proactive Investors UK
HC Wainwright Has Positive Forecast for CRDL FY2024 Earnings - Defense World
FY2024 Earnings Forecast for CRDL Issued By HC Wainwright - MarketBeat
RAD 202 receives approval to start Phase 1 therapeutic trial - Investing News Network
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - The Manila Times
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis - Investing News Network
PRISM MarketView Features Q&A with President and CEO David - GlobeNewswire
HC Wainwright Reiterates Buy Rating for Cardiol Therapeutics (NASDAQ:CRDL) - MarketBeat
Cardiex Completes Placement Ahead of CONNEQT US Launch - Investing News Network
BPH Global receives funding commitment of A$100,000 - Investing News Network
Cardiol Therapeutics Inc. (TSE:CRDL) Senior Officer Bernard Lim Acquires 10,000 Shares of Stock - MarketBeat
David Elsley Buys 40,000 Shares of Cardiol Therapeutics Inc. (TSE:CRDL) Stock - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1%What's Next? - MarketBeat
Cardiol Therapeutics (TSE:CRDL) Trading Down 2.1% – Here’s What Happened - Defense World
Townsquare Capital LLC Buys New Shares in Cardiol Therapeutics Inc. (NASDAQ:CRDL) - Defense World
Cardiol Therapeutics (STU:CT9) Momentum Rank : 6 (As of Dec. 05, 2024) - GuruFocus.com
Cardiol Therapeutics (OTCMKTS:CRTPF) Shares Down 3.1% – Should You Sell? - Defense World
Cardiol Therapeutics (TSX:CRDL) Price-to-Operating-Cash-Flo - GuruFocus.com
CRDL (Cardiol Therapeutics) 50-Day SMA : $1.88 (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (TSX:CRDL) Enterprise Value : C$168.30 Mil (As of Dec. 01, 2024) - GuruFocus.com
Cardiol Therapeutics (FRA:CT9) Price-to-Free-Cash-Flow : N/A (As of Dec. 01, 2024) - GuruFocus.com
3 Penny Stocks Ready to Break Out in 2025 - MarketBeat
3 Penny Stocks Ready To Break Out In 2025 - Barchart
Cardiol Therapeutics (CRDL-Q) QuotePress Release - The Globe and Mail
Cardiol Therapeutics (FRA:CT9) Cyclically Adjusted Revenue per Share : €0.00 (As of Sep. 2024) - GuruFocus.com
Game-Changing Solution for Heart Inflammation? | David Elsley – Cardiol Therapeutics - The Deep Dive
HC Wainwright Issues Optimistic Estimate for CRDL Earnings - Defense World
Comparing Cardiol Therapeutics (NASDAQ:CRDL) & Gilead Sciences (NASDAQ:GILD) - Defense World
What is HC Wainwright's Forecast for CRDL FY2024 Earnings? - MarketBeat
Equities Analysts Set Expectations for CRDL FY2024 Earnings - Defense World
Cardiol Therapeutics (NASDAQ:CRDL) Earns Buy Rating from HC Wainwright - Defense World
Cardiol Therapeutics Inc (CRDL) 財務データ
収益
当期純利益
現金流量
EPS
1.19%
0.06%
大文字化:
|
ボリューム (24 時間):